A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

NCT06099782 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Melanoma

Interventions

BIOLOGICAL: Pembrolizumab (+) Berahyaluronidase alfa
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC